Lilly rides Mounjaro, Zepbound to better
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles
Explainer: What makes China magnet for multinational corporations?
BEIJING, April 29 (Xinhua) -- China is becoming even more attractive to foreign investors, as the la2024-05-01Innovating Rice Planting with Passion
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-01Street Vendor in SW China's Sichuan Wins Hearts with English Fluency
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-01- Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-01
New Jersey seeks fourth round of offshore wind farm proposals as foes push back
LONG BEACH TOWNSHIP, N.J. (AP) — New Jersey is seeking a new round of proposals to build wind energy2024-05-01The IRS is quicker to answer the phone on this Tax Day
WASHINGTON (AP) — On this Tax Day, the IRS is promoting the customer service improvements the agency2024-05-01
atest comment